DTx Pharma
AcquiredSan Diego, US · Founded 2017 · Delaware corporation · 4 known investors
Find your way into DTx Pharma
170 people in our graph share verified history with the DTx Pharma team — schools, employers, funds. One of them is your warm intro.
Karthik Ardhanareeswaranunlockedknows Arthur Suckow · together at Johnson & Johnson (overlapped)
×3knows the team · via University of California at San Diego
×4knows the team · via Johnson & Johnson
knows the team · via UC San Diego School of Medicine
×3knows the team · via University of Delaware
The page presented is corporate content for Novartis, a pharmaceutical company that develops medicines across areas such as multiple sclerosis, cardiovascular disease, and oncology. The content covers clinical trial results, financial results, and annual reporting rather than the expected dtxpharma.com company.
Founders & leadership
DTx Pharma was founded in 2017 by Arthur T Suckow and Arthur Suckow, Ph.D..
AT
Arthur T SuckowinCo-founder · CEO2017–2023Arthur T Suckow is an executive officer at DTx Pharma with expertise in drug discovery for metabolic and cardiovascular diseases, including hands-on experience in beta cell function, insulin signaling, and liver metabolism across in vitro, ex vivo, and in vivo models.
AS
Arthur Suckow, Ph.D.inCo-founder · CEO2017–2023Arthur Suckow holds a Ph.D. and has developed expertise in drug discovery for metabolic disorders, with hands-on research experience in metabolic pathways, beta cell biology, and insulin sensitization using small molecule and biologic approaches targeting GPCRs and nuclear receptors.
Investors · 4
Reported raises · per SEC filings
Form D private placements$113.4M disclosed across 4 rounds · 2017–2021
▶$100.2MraisedMar 2021 · 22 investors · PharmaceuticalsRule 506(b)
▶$100.2MraisedMar 2021 · 22 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Arthur SuckowExecutive Officer, Director
- John RundyDirector
- Jeffrey FriedmanExecutive Officer, Director
- Niki UpperExecutive Officer
- Matthew HammondDirector
- Daniel BeckerDirector
- Tim ScottDirector
- Andrew AdamsDirector
- Offering amount
- $100.2M
- Amount sold
- $100.2M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$200KraisedJul 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$200KraisedJul 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey FriedmanExecutive Officer, Director
- John GrundyDirector
- Arthur SuckowExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $200K
- Minimum investment
- $50K
- Placement agents
- na
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$12MraisedSep 2019 · 60 investors · PharmaceuticalsRule 506(b)
▶$12MraisedSep 2019 · 60 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Arthur T SuckowExecutive Officer, Director
- John GrundyDirector
- Jeffrey FriedmanDirector
- Offering amount
- $12.5M
- Amount sold
- $12M
- Minimum investment
- $10K
- Placement agents
- na
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$1MraisedJun 2018 · 15 investors · PharmaceuticalsRule 506(b)
▶$1MraisedJun 2018 · 15 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Arthur T SuckowExecutive Officer
- Offering amount
- $2M
- Amount sold
- $1M
- Minimum investment
- $1
- Placement agents
- na
- First sale
- Aug 2017
- Incorporated
- Limited Liability Company, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $387.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2020 | $313K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $321.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $301.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $225.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does DTx Pharma do?
- The page presented is corporate content for Novartis, a pharmaceutical company that develops medicines across areas such as multiple sclerosis, cardiovascular disease, and oncology. The content covers clinical trial results, financial results, and annual reporting rather than the expected dtxpharma.com company.
- Who founded DTx Pharma?
- DTx Pharma was founded by Arthur T Suckow, Arthur Suckow, Ph.D. in 2017.
- Who are DTx Pharma's investors?
- DTx Pharma's investors include Access Biotechnology, ExSight Ventures, RA Capital, Janus Henderson Investors.
- How much funding has DTx Pharma raised?
- DTx Pharma has disclosed $113.4M raised across 4 rounds.
- Where is DTx Pharma headquartered?
- DTx Pharma is headquartered in San Diego, US.